Table 3.
Distribution of confirmed cases of ILI and SARS, according to the individual variables selected
| Variables | Overall | ILI | SARS | Statistic parameter | P-value | |||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | Chi-square | ||
| Age group | 18,456 | 0.000 | ||||||
| 0–9 years | 5105 | 2.1% | 4369 | 2.5% | 736 | 1.1% | – | – |
| 10–19 years | 7478 | 3.1% | 6442 | 3.6% | 1036 | 1.6% | – | – |
| 20–29 years | 30,426 | 12.5% | 25,014 | 14.0% | 5412 | 8.3% | – | – |
| 30–39 years | 53,654 | 22.0% | 43,466 | 24.4% | 10,188 | 15.6% | – | – |
| 40–49 years | 51,913 | 21.3% | 40,163 | 22.5% | 11,750 | 18.0% | – | – |
| 50–59 years | 40,729 | 16.7% | 29,536 | 16.6% | 11,193 | 17.1% | – | – |
| 60–69 years | 27,034 | 11.1% | 16,751 | 9.4% | 10,283 | 15.8% | – | – |
| 70–79 years | 15,273 | 6.3% | 7356 | 4.1% | 7917 | 12.1% | – | – |
| 80 years or older | 10,812 | 4.5% | 4055 | 2.3% | 6757 | 10.4% | – | – |
| No Information | 1085 | 40.0% | 1079 | 60.0% | 6 | 0.0% | – | – |
| Sex | 7 | 0.008 | ||||||
| Female | 127,677 | 52.4% | 93,740 | 52.6% | 33,937 | 52.0% | – | – |
| Male | 115,832 | 47.6% | 84,491 | 47.4% | 31,341 | 48.0% | – | – |
| Race/skin color | 723 | 0.000 | ||||||
| Brown | 80,162 | 32.9% | 60,806 | 34.1% | 19,356 | 29.7% | – | – |
| Asian | 11,875 | 4.9% | 9808 | 5.5% | 2067 | 3.2% | – | – |
| White | 79,495 | 32.6% | 58,986 | 33.1% | 20,509 | 31.4% | – | – |
| Indigenous | 491 | 0.2% | 441 | 0.2% | 50 | 0.1% | – | – |
| Black | 15,802 | 6.5% | 11,007 | 6.2% | 4795 | 7.3% | – | – |
| Not reported | 55,684 | 22.9% | 37,183 | 20.9% | 18,501 | 28.3% | – | – |
| Presence of signs and symptoms | – | – | ||||||
| Fever | 93,102 | 38.3% | 53,721 | 30.1% | 39,381 | 60.3% | 21,309 | 0.000 |
| Cough | 108,434 | 44.5% | 65,565 | 36.8% | 42,869 | 65.7% | 19,156 | 0.000 |
| Headache | 33,020 | 13.6% | 24,667 | 13.8% | 8353 | 12.8% | 7 | 0.007 |
| Sneezing | 1636 | 0.7% | 1249 | 0.7% | 387 | 0.6% | 4 | 0.040 |
| Odynophagia | 42,797 | 17.6% | 28,276 | 15.9% | 14,521 | 22.2% | 1749 | 0.000 |
| Dyspnea | 52,376 | 21.5% | 0 | 0.0% | 52,376 | 80.2% | 191,664 | 0.000 |
| Runny nose | 18,139 | 7.4% | 13,931 | 7.8% | 4208 | 6.4% | 75 | 0.000 |
| Diarrhea | 12,801 | 5.3% | 9059 | 5.1% | 3742 | 5.7% | 78 | 0.000 |
| Muscle pain | 23,015 | 9.5% | 16,163 | 9.1% | 6852 | 10.5% | 199 | 0.000 |
| Loss of smell | 21,764 | 8.9% | 16,272 | 9.1% | 5492 | 8.4% | 6 | 0.020 |
| Loss of taste | 15,478 | 6.4% | 11,826 | 6.6% | 3652 | 5.6% | 46 | 0.000 |
| Presence of comorbidities | – | – | ||||||
| Cardiovascular disease | 25,845 | 10.6% | 10,296 | 5.8% | 15,549 | 23.8% | 27,410 | 0.000 |
| Diabetes mellitus | 15,500 | 6.4% | 5333 | 3.0% | 10,167 | 15.6% | 21,888 | 0.000 |
| Chronic kidney disease | 2203 | 0.9% | 530 | 0.3% | 1673 | 2.6% | 4930 | 0.000 |
| Chronic respiratory disease | 6318 | 2.6% | 3036 | 1.7% | 3282 | 5.0% | 2079 | 0.000 |
| Immunodeficiency/ immunosuppression | 2527 | 1.0% | 1226 | 0.7% | 1301 | 2.0% | 1897 | 0.000 |
| Evolution | 30,186 | 0.000 | ||||||
| Death | 18,076 | 7.4% | 2097 | 1.2% | 15,979 | 24.5% | – | – |
| Non-death | 225,433 | 92.6% | 176,134 | 98.8% | 49,299 | 75.5% | – | – |
| Total | 243,509 | 100.0% | 178,231 | 73.19% | 65,278 | 26.81% | – | – |
Note: confirmed cases of COVID-19, state of Rio de Janeiro, March–September 2020